Clinical trial
The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions
NCT05033964 is registered in ClinicalTrials.gov with Elixir Medical Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions
- Lead sponsor
- Elixir Medical Corporation
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- December 15, 2021
- Completion date
- March 31, 2026
- Enrollment
- 200 (estimated)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.